Phenotypically, mutant ASXL1 impairs the BAP1-ASXL1-FOXK1/K2 transcriptional nexus and downregulates TXNIP, VHL, and SOCS1/2, and consequently promotes glucose metabolism and enhances oncogenic HIF-1α and JAK-STAT3 signaling pathways known to be altered in hematological malignancies. The gene discussed is ASXL1; the disease is hematologic disorder.